MCS 110

Drug Profile

MCS 110

Alternative Names: MCS110

Latest Information Update: 23 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Novartis; Novartis Oncology
  • Class Monoclonal antibodies
  • Mechanism of Action Macrophage colony stimulating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Giant cell tumour of tendon sheath; Pigmented villonodular synovitis
  • Phase I/II Solid tumours
  • Discontinued Bone metastases; Prostate cancer

Most Recent Events

  • 22 Sep 2017 Washington University School of Medicine in collaboration with Novartis Pharmaceuticals plans a phase I trial (Combination therapy) for Breast cancer in USA in December 2017 (NCT03285607)
  • 26 Jun 2017 Phase-I/II clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater, Late-stage disease) in USA, South Korea, Germany (Parenteral) before June 2017 (NCT02807844)
  • 10 May 2017 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in France (Parenteral) (EudraCT2016-000210-29)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top